SALUTARIS-MEDICAL
6.9.2016 06:09:41 CEST | Business Wire | Press release
Today, Salutaris Medical Devices, Inc. (SalutarisMD® ) announced that during its upcoming presentation at the Ophthalmology Futures European Forum on September 8, the Company will introduce its new generation, commercial ready, episcleral brachytherapy applicator system. The presentation by Dr. Laurence Marsteller, CEO, will discuss how the new SalutarisMD system (SMD-DA™) is designed to deliver improved dosimetry to wet AMD lesions and improved ease of use for retinal surgeons. The Company will also display the system at its exhibitor’s booth. ISO audits for certification and CE application are underway and the Company expects to receive ISO 13485 certification and the CE Mark on the commercial product by year end.
The Company recently received US regulatory approval for an upcoming clinical study utilizing the new and improved device. The Company has successfully completed a previous study with a first generation clinical device. While that study was not intended to be extrapolated for statistical significance, individual subject results were tracked. In three of the four treatment-naïve patients and one of the two chronically treated wet AMD patients, best corrected visual acuity (BCVA) improved at two years following SMD-1™ treatment (range: +4 to +25 ETDRS letters). In addition, two treatment-naïve patients did not require any further anti-VEGF injections during the following two years.
As wet AMD is the leading cause of blindness worldwide, there is an urgent and compelling need for new therapies that improve visual outcomes and lower the burden of care. Dr. Laurence Marsteller commented that, “Our new commercial ready applicator system is a significant marker of SalutarisMD’s continued progress and we are looking forward to positively affecting patient outcomes.”
(Caution: Investigational Device, Limited to Investigational Use).
About SalutarisMD
SalutarisMD (Salutaris Medical Devices, Inc. and Salutaris Medical Devices, Ltd.) is a pre-revenue medical device company developing an investigational ophthalmic treatment for wet age-related Macular Degeneration (wet AMD). The SalutarisMD patented technology incorporates a minimally invasive single-use brachytherapy procedure that can be performed in an outpatient setting in approximately 15 minutes. This method delivers localized tissue irradiation that is performed under the direct care and expertise of a retina specialist. For more information visit www.SalutarisMD.com or www.SalutarisMD.co.uk .
About Ophthalmology Futures Forums
Ophthalmology Futures Forums are clinician-driven innovation meetings focusing on technology as well as financing, market access and commercialisation of new ophthalmic products. They cover all aspects of global innovation in ophthalmic devices, diagnostics and pharmaceuticals. For more information visit http://www.ophthalmology-futures.com .
Salutaris Medical Devices, Inc.
4340 N. Campbell Ave. Suite 266
Tucson,
AZ 85718
+1 520-638-7518
www.SalutarisMD.com
Salutaris Medical Devices, Ltd.
Level 1, Bessemer Building Imperial
College
London SW72AZ +44 (0) 203 282 7166
www.SalutarisMD.co.uk
View source version on businesswire.com: http://www.businesswire.com/news/home/20160905005056/en/
Contact:
SalutarisMD
Joanne Vitali, Communications Director
+1
610-518-5405
jvitali@SalutarisMD.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vonage and C3 AI Partner on Network-Enabled, Agentic AI Field Services Solution for Mobile Workforces11.2.2026 09:30:00 CET | Press release
Designed for mission-critical field operations, the joint solution combines autonomous and assisted AI with Vonage communications and network APIs for those working beyond the enterprise edge Vonage, part of Ericsson (NASDAQ: ERIC), today announced a strategic collaboration with C3 AI (NYSE: AI), a leading Enterprise AI application software provider, to launch C3 AI Field Services, a module of the C3 AI Asset Performance Suite of products, integrated with Vonage APIs. The AI-first module combines C3 AI’s powerful Enterprise AI capabilities with Vonage’s cutting-edge Communications APIs (Voice and Video) and Network APIs (Quality on Demand and Verify), to deliver superior performance, reliability and experiences for mobile enterprise field operations. This collaboration builds on a broader network-powered solutions offering from Vonage where application-aware networking, including advanced connectivity capabilities such as Quality on Demand (QoD), can be applied to support critical fiel
Mobileum and NOHOLD Launch White-Labeled AI Assistant Offering for Telecom Enterprise Customers11.2.2026 09:00:00 CET | Press release
First product release following the companies’ strategic AI alliance enables operators to monetize AI services for SME/SMBs through existing telco channels Mobileum Inc. (“Mobileum”), a leading global provider of analytics and network solutions, and NOHOLD, a leader in enterprise-grade AI assistant platforms, have announced the launch of a new white-labeled AI Assistant solution designed specifically for telecom operators serving small and medium-sized enterprises (SME/SMBs). The new offering builds on the strategic AI alliance announced in September 2025, moving from concept to a market-ready solution. Telecom operators can now offer branded AI Assistant services that help SME/SMBs enhance customer engagement, drive sales, and improve productivity through AI technology, with operators providing the tools so SME/SMBs avoid managing complex AI themselves. As traditional connectivity revenues continue to be under pressure, SME/SMBs are seeking value-added digital services from their tele
Merus Power leverer et energilagringssystem til ekstreme arktiske forhold11.2.2026 08:00:00 CET | Pressemeddelelse
Merus Power Oyj har indgået en aftale om levering af et batterienergilagringssystem til en værdi af cirka 13 mio. euro med Neve Oy. Anlægget på 30 MW/80 MWh er designet til at fungere under ekstremt kolde forhold og vil blive leveret til Rovaniemi ved udgangen af 2026. Virksomhederne har desuden indgået aftale om omfattende drifts- og vedligeholdelsestjenester for energilagringsanlægget. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20260205135896/da/ Merus Power delivered the first grid forming battery energy storage systems in the Nordics last year. The grid forming BESS to be deployed in Lapland is also designed to withstand extreme Arctic conditions. Energilagringsanlægget er konstrueret til at fungere pålideligt under arktiske forhold og kan modstå temperaturer helt ned til -50 °C samt kraftigt snefald og is. Systemet anvender grid forming-teknologi, som understøtter elnettets inerti og styrker stabiliteten i el-system
Galderma Expands Restylane® Portfolio in Japan With Launch of OBT™ Hyaluronic Acid Injectables Restylane Defyne™ and Refyne™11.2.2026 07:00:00 CET | Press release
Restylane® Refyne™ and Restylane Defyne™ are the first Optimal Balance Technology (OBT™) hyaluronic acid injectables ever approved and launched in Japan, bringing advanced flexibility and natural movement to the market1,2 This expands Galderma’s Restylane portfolio in Japan to four products, enabling treatment of a wider spectrum of patient and practitioner needs3,4 These two new launches underscore Galderma’s accelerating growth across the Japan & Asia Pacific (JPAC) region Galderma (SIX: GALD), the pure-play dermatology category leader, has announced the launch of Restylane Defyne and Restylane Refyne: the first OBT‑based hyaluronic acid injectables ever authorized in Japan.1,2 The products – designed for injection into the mid-to-deep dermis for the correction of moderate to severe facial wrinkles and folds – are now commercially available in the market.1,2 Restylane Defyne and Refyne leverage the unique balance of softness, flexibility, and support delivered by Galderma’s proprieta
Suzano Reports Record Sales and Continued Improvements in Operational Efficiency in 202511.2.2026 00:44:00 CET | Press release
Suzano, the world’s largest pulp producer, announces its results for both the final quarter (4Q25) and the full year (2025), reporting record annual sales volumes and net revenue. The company also reported an improvement in its cash cost of pulp production, reflecting the drive for improved operational efficiency. Pulp and paper sales reached 14.2 million tonnes, a 15% increase compared to 2024. This performance was driven primarily by the strong operational contribution of the Ribas do Rio Pardo pulp mill, which began production in July 2024, and the company’s paper mills in the United States. As a result, Suzano’s full‑year net revenue reached a record R$50 billion in 2025. The company’s consistent focus on efficiency and cost discipline also contributed to a meaningful reduction in the cash cost of pulp production. Excluding downtime, the annual cash cost was R$817 per tonne, reaching its lowest annual level since 2021. Operational efficiency also helped Suzano deliver operating cas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom